EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS

Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news